Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes

New Company Aims To Achieve $1bn Of Synergies Through Restructuring

Executive Summary

Nearly 16 months after it was first announced, the $12bn merger of Mylan and Pfizer’s Upjohn has completed, with the resulting company Viatris preparing to unveil restructuring plans by the end of 2020.

You may also be interested in...



Consolidation And COVID See Industry Top 10 Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, the leaders of the pack in the Generics Bulletin Top 50 have once again seen significant changes in 2021.

Perjeta Among Biosimilar Targets As Viatris Insists It Can ‘Do A Lot More’

At Viatris’ inaugural investor day, management spoke at length about the company’s ambitions for biosimilars, underlining that the company currently had no plans to expand its manufacturing footprint at the present time.

Pfizer Biosimilars Sales Hit $1.5bn In 2020 As US Revenues Double

Pfizer’s US biosimilars sales approached $1bn last year, following a number of launches and continued uptake for key products, while revenues in international markets, especially Europe, also increased.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel